Pathology & Oncology Research最新文献

{"title":"NAD+ biosynthesis metabolism predicts prognosis and indicates immune microenvironment for breast cancer.","authors":"Yuting Yang,&nbsp;Ze Wang,&nbsp;Mengqi He,&nbsp;Lihong Diao,&nbsp;Biyue Yu,&nbsp;Dong Li","doi":"10.3389/pore.2023.1610956","DOIUrl":"https://doi.org/10.3389/pore.2023.1610956","url":null,"abstract":"<p><p>The growing evidence implies that tumor cells need to increase NAD+ levels by upregulating NAD+ biosynthesis to satisfy their growth demand. NAD+ biosynthesis metabolism is implicated in tumor progression. Breast cancer (BC) is the most common malignant malignancy in the world. Nevertheless, the prognostic significance of NAD+ biosynthesis and its relationship with the tumor immune microenvironment in breast cancer still need further investigation. In this study, we obtained the mRNA expression data and clinical information of BC samples from public databases and calculated the level of NAD+ biosynthesis activity by single-sample gene set enrichment analysis (ssGSEA). We then explored the relationship between the NAD+ biosynthesis score, infiltrating immune cells, prognosis significance, immunogenicity and immune checkpoint molecules. The results demonstrated that patients with high NAD+ biosynthetic score displayed poor prognosis, high immune infiltration, high immunogenicity, elevated PD-L1 expression, and might more benefit from immunotherapy. Taken together, our studies not only deepened the understanding of NAD+ biosynthesis metabolism of breast cancer but also provided new insights into personalized treatment strategies and immunological therapies to improve the outcomes of breast cancer patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610956"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9245852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma.","authors":"Hongyu Wang,&nbsp;Liqun Yang,&nbsp;Qiuyao Li,&nbsp;Haiyun Song,&nbsp;Hong Ji","doi":"10.3389/pore.2023.1611051","DOIUrl":"https://doi.org/10.3389/pore.2023.1611051","url":null,"abstract":"<p><p>Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes. Eight mutations were identified in its Hodgkin component through next-generation sequencing. In addition, we reviewed the published cases of composite mantle cell lymphoma and classical Hodgkin lymphoma and summarized the molecular changes of reported cases as well as the current case to explore the possible pathway of histogenesis.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611051"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9245854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The roles of NOP56 in cancer and SCA36.","authors":"Shimin Zhao,&nbsp;Dongdong Zhang,&nbsp;Sicheng Liu,&nbsp;Jun Huang","doi":"10.3389/pore.2023.1610884","DOIUrl":"https://doi.org/10.3389/pore.2023.1610884","url":null,"abstract":"<p><p>NOP56 is a highly conserved nucleolar protein. Amplification of the intron GGCCTG hexanucleotide repeat sequence of the <i>NOP56</i> gene results in spinal cerebellar ataxia type 36 (SCA36). NOP56 contains an N-terminal domain, a coiled-coil domain, and a C-terminal domain. Nucleolar protein NOP56 is significantly abnormally expressed in a number of malignant tumors, and its mechanism is different in different tumors, but its regulatory mechanism in most tumors has not been fully explored. NOP56 promotes tumorigenesis in some cancers and inhibits tumorigenesis in others. In addition, NOP56 is associated with methylation in some tumors, suggesting that NOP56 has the potential to become a tumor-specific marker. This review focuses on the structure, function, related signaling pathways, and role of NOP56 in the progression of various malignancies, and discusses the progression of NOP56 in neurodegenerative and other diseases.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610884"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients' samples.","authors":"Ployploen Phikulsod,&nbsp;Sanya Sukpanichnant,&nbsp;Chutima Kunacheewa,&nbsp;Thaweesak Chieochansin,&nbsp;Mutita Junking,&nbsp;Pa-Thai Yenchitsomanus","doi":"10.3389/pore.2023.1610844","DOIUrl":"https://doi.org/10.3389/pore.2023.1610844","url":null,"abstract":"<p><p>Wilms tumor 1 (WT1) is a promising target antigen for cancer immunotherapy. However, WT1 protein expression and its clinical correlation in multiple myeloma (MM) patients are still limited. We, therefore, investigated WT1 expression in 142 bone marrow and plasmacytoma samples of MM patients at different stages of the disease by immunohistochemistry. The correlations between WT1 expression and clinical parameters or treatment outcomes were evaluated. The overall positive rate of WT1 expression was 91.5%; this high prevalence was found in both bone marrow and plasmacytoma samples, regardless of the disease status. Cytoplasmic WT1 expression was correlated with high serum free light chain ratio at presentation. However, no significant association between WT1 expression and treatment outcome was observed. This study confirms the high prevalence of WT1 expression in an Asian cohort of MM, encouraging the development of immunotherapy targeting WT1 in MM patients, particularly in those with extramedullary plasmacytoma or relapsed disease.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610844"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10692325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between radiomics features of DCE-MRI and CD8⁺ and CD4⁺ TILs in advanced gastric cancer.","authors":"Huizhen Huang,&nbsp;Zhiheng Li,&nbsp;Yue Xia,&nbsp;Zhenhua Zhao,&nbsp;Dandan Wang,&nbsp;Hongyan Jin,&nbsp;Fang Liu,&nbsp;Ye Yang,&nbsp;Liyijing Shen,&nbsp;Zengxin Lu","doi":"10.3389/pore.2023.1611001","DOIUrl":"https://doi.org/10.3389/pore.2023.1611001","url":null,"abstract":"<p><p><b>Objective:</b> The aim of this investigation was to explore the correlation between the levels of tumor-infiltrating CD8⁺ and CD4⁺ T cells and the quantitative pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced gastric cancer. <b>Methods:</b> We retrospectively analyzed the data of 103 patients with histopathologically confirmed advanced gastric cancer (AGC). Three pharmacokinetic parameters, K_ep, K^trans, and V_e, and their radiomics characteristics were obtained by Omni Kinetics software. Immunohistochemical staining was used to determine CD4⁺ and CD8⁺ TILs. Statistical analysis was subsequently performed to assess the correlation between radiomics characteristics and CD4⁺ and CD8⁺ TIL density. <b>Results:</b> All patients included in this study were finally divided into either a CD8⁺ TILs low-density group (<i>n</i> = 51) (CD8⁺ TILs < 138) or a high-density group (<i>n</i> = 52) (CD8⁺ TILs ≥ 138), and a CD4⁺ TILs low-density group (<i>n</i> = 51) (CD4⁺ TILs < 87) or a high-density group (<i>n</i> = 52) (CD4⁺ TILs ≥ 87). ClusterShade and Skewness based on K_ep and Skewness based on K^trans both showed moderate negative correlation with CD8⁺ TIL levels (<i>r</i> = 0.630-0.349, <i>p</i> < 0.001), with ClusterShade based on K_ep having the highest negative correlation (<i>r</i> = -0.630, <i>p</i> < 0.001). Inertia-based K_ep showed a moderate positive correlation with the CD4⁺ TIL level (<i>r</i> = 0.549, <i>p</i> < 0.001), and the Correlation based on K_ep showed a moderate negative correlation with the CD4⁺ TIL level, which also had the highest correlation coefficient (<i>r</i> = -0.616, <i>p</i> < 0.001). The diagnostic efficacy of the above features was assessed by ROC curves. For CD8⁺ TILs, ClusterShade of K_ep had the highest mean area under the curve (AUC) (0.863). For CD4⁺ TILs, the Correlation of K_ep had the highest mean AUC (0.856). <b>Conclusion:</b> The radiomics features of DCE-MRI are associated with the expression of tumor-infiltrating CD8⁺ and CD4⁺ T cells in AGC, which have the potential to noninvasively evaluate the expression of CD8⁺ and CD4⁺ TILs in AGC patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611001"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous tracheostomy: Comparison of three different methods with respect to tracheal cartilage injury in cadavers-Randomized controlled study.","authors":"Fruzsina Bódis,&nbsp;Gábor Orosz,&nbsp;József T Tóth,&nbsp;Marcell Szabó,&nbsp;László Gergely Élő,&nbsp;János Gál,&nbsp;Gábor Élő","doi":"10.3389/pore.2023.1610934","DOIUrl":"https://doi.org/10.3389/pore.2023.1610934","url":null,"abstract":"<p><p><b>Background:</b> Performing tracheostomy improves patient comfort and success rate of weaning from prolonged invasive mechanical ventilation. Data suggest that patients have more benefit of percutaneous technique than the surgical procedure, however, there is no consensus on the percutaneous method of choice regarding severe complications such as late tracheal stenosis. Aim of this study was comparing incidences of cartilage injury caused by different percutaneous dilatation techniques (PDT), including Single Dilator, Griggs' and modified (bidirectional) Griggs' method. <b>Materials and methods:</b> Randomized observational study was conducted on 150 cadavers underwent post-mortem percutaneous tracheostomy. Data of cadavers including age, gender and time elapsed from death until the intervention (more or less than 72 h) were collected and recorded. Primary and secondary outcomes were: rate of cartilage injury and cannula malposition respectively. <b>Results:</b> Statistical analysis revealed that method of intervention was significantly associated with occurrence of cartilage injury, as comparing either standard Griggs' with Single Dilator (<i>p</i> = 0.002; OR: 4.903; 95% CI: 1.834-13.105) or modified Griggs' with Single Dilator (<i>p</i> < 0.001; OR: 6.559; 95% CI: 2.472-17.404), however, no statistical difference was observed between standard and modified Griggs' techniques (<i>p</i> = 0.583; OR: 0.748; 95% CI: 0.347-1.610). We found no statistical difference in the occurrence of cartilage injury between the early- and late post-mortem group (<i>p</i> = 0.630). Neither gender (<i>p</i> = 0.913), nor age (<i>p</i> = 0.529) influenced the rate of cartilage fracture. There was no statistical difference between the applied PDT techniques regarding the cannula misplacement/malposition. <b>Conclusion:</b> In this cadaver study both standard and modified Griggs' forceps dilatational methods were safer than Single dilator in respect of cartilage injury.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610934"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC.","authors":"Anke Behnke,&nbsp;Anne Cayre,&nbsp;Giovanna De Maglio,&nbsp;Giuseppe Giannini,&nbsp;Lionel Habran,&nbsp;Marina Tarsitano,&nbsp;Massimiliano Chetta,&nbsp;David Cappellen,&nbsp;Alexandra Lespagnol,&nbsp;Cecile Le Naoures,&nbsp;Gabriella Massazza,&nbsp;Annarita Destro,&nbsp;Irina Bonzheim,&nbsp;Achim Rau,&nbsp;Achim Battmann,&nbsp;Bettina Kah,&nbsp;Emmanuel Watkin,&nbsp;Michael Hummel","doi":"10.3389/pore.2023.1610707","DOIUrl":"https://doi.org/10.3389/pore.2023.1610707","url":null,"abstract":"<p><p>Accurate testing for epidermal growth factor receptor (<i>EGFR</i>) variants is essential for informing treatment decisions in non-small cell lung cancer (NSCLC). Automated diagnostic workflows may allow more streamlined initiation of targeted treatments, where appropriate, while comprehensive variant analysis is ongoing. FACILITATE, a real-world, prospective, multicenter, European study, evaluated performance and analytical turnaround time of the Idylla™ EGFR Mutation Test compared with local reference methods. Sixteen sites obtained formalin-fixed paraffin-embedded biopsy samples with ≥ 10% neoplastic cells from patients with NSCLC. Consecutive 5 μm sections from patient samples were tested for clinically relevant NSCLC-associated <i>EGFR</i> variants using the Idylla™ EGFR Mutation Test and local reference methods; performance (concordance) and analytical turnaround time were compared. Between January 2019 and November 2020, 1,474 parallel analyses were conducted. Overall percentage agreement was 97.7% [<i>n</i> = 1,418; 95% confidence interval (CI): 96.8-98.3], positive agreement, 87.4% (<i>n</i> = 182; 95% CI: 81.8-91.4) and negative agreement, 99.2% (<i>n</i> = 1,236; 95% CI: 98.5-99.6). There were 38 (2.6%) discordant cases. Ninety percent of results were returned with an analytical turnaround time of within 1 week using the Idylla™ EGFR Mutation Test versus ∼22 days using reference methods. The Idylla™ EGFR Mutation Test performed well versus local methods and had shorter analytical turnaround time. The Idylla™ EGFR Mutation Test can thus support application of personalized medicine in NSCLC.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610707"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9190336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.","authors":"Christopher T Boniface,&nbsp;Paul T Spellman","doi":"10.3389/pore.2023.1611133","DOIUrl":"https://doi.org/10.3389/pore.2023.1611133","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610103.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611133"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma.","authors":"Yu-Ting Ma,&nbsp;Yan Li,&nbsp;Li Yan,&nbsp;Fang Hua,&nbsp;Dong-Guan Wang,&nbsp;Guo-Ying Xu,&nbsp;Hong-Lan Yang,&nbsp;Ying-Jie Xue,&nbsp;Ye-Jun Qin,&nbsp;Dan Sha,&nbsp;Hao Ning,&nbsp;Miao-Qing Zhao,&nbsp;Zhi-Gang Yao","doi":"10.3389/pore.2023.1610989","DOIUrl":"https://doi.org/10.3389/pore.2023.1610989","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610638.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610989"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Urothelial carcinoma of the renal pelvis with trophoblastic differentiation: A rare case report and review of literature.","authors":"Zhuo Wang,&nbsp;Jinsui Wang,&nbsp;Wenwen Zhang,&nbsp;Daoying Wang,&nbsp;Xiaojun Wang,&nbsp;Xiaoqin Liang","doi":"10.3389/pore.2023.1610856","DOIUrl":"https://doi.org/10.3389/pore.2023.1610856","url":null,"abstract":"<p><p>We report a rare case of urothelial carcinoma (UC) of the renal pelvis with trophoblastic differentiation that occurred in a 55-year-old male patient. The patient presented with gross hematuria and paroxysmal lumbago pain 5 months ago. The enhanced computed tomography (CT) scan demonstrated a large space occupying lesion in the left kidney and multiple retroperitoneal lymph node enlargements. Histologically, high-grade infiltrating urothelial carcinoma (HGUC) contained giant cells which were positive for beta-human chorionic gonadotropin (β-hCG). Three weeks after resection, positron emission tomography and computed tomography (PET-CT) scan showed multiple nodules of metastasis in the left renal region, extensive systemic muscle, bone, lymph node, liver and bilateral lung metastases. The patient underwent bladder perfusion chemotherapy and gemcitabine combined with cisplatin chemotherapy regimens. This is the eighth documented case of UC of the renal pelvis with trophoblastic differentiation. Due to its rarity and extremely poor prognosis, it is important to clarify the characteristics of the disease and make an accurate and prompt diagnosis.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610856"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10781266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}